[Dexrazoxane and cardiotoxicity in repeatedly treated patients].

M Trnĕný

Vnitr Lek 2004, 50(6):417-418

[The benefit of a fixed combination of antihypertensives in hypertension treatment].

Karel Horký

Vnitr Lek 2004, 50(6):418, 420

[Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes].

P Horák, Z Hermanová, M Ordeltová, L Faltýnek, L Kusá, M Budíková, V Vavrdová, D Opíchalová, H Ciferská, V Scudla

Vnitr Lek 2004, 50(6):422-427

Goal of this study was to monitor levels of serum neopterin and soluble interleukin-2 receptor (sIL-2r) and to evaluate their importance in monitoring activity of systemic lupus erythematodes (SLE). Levels of serum neopterin, anti-dsDNA antibodies, C3, C4 complement components, nucleosomes antibodies, IL-10, fas ligand, soluble thrombomodulin, sVCAM-1, and sICAM-1 were measured in a group of 52 patients with SLE. Positive correlations were proved between neopterin concentrations and disease activity (ECLAM), levels of sVCAM-1, sICAM-1, sIL-2r and thrombomodulin, further between sIL-2r level and disease activity (ECLAM), and concentrations sVCAM-1,...

[Assessment of speed of an anti-platelet effect after two different doses of acetylsalicylic acid by flocculation].

M Malý, J Vojácek, I Hadacová, M Mates, P Hájek, V Durdil

Vnitr Lek 2004, 50(6):428-433

UNLABELLED: Acetylsalicylic acid inhibits aggregation of blood platelets through affecting arachidon acid metabolism--a precursor of thromboxan which is a strong platelet aggregation inhibitor. A standard method for measurement of aggregation activity blockade (in percents) of platelet rich plasma is turbidimetric aggregomethry based on spectrophotometric principle. According to results of recent studies administration of acetylsalicylic acid is one of the basic pillars of prevention of thrombotic complications in atherosclerotic arterial disease. Acetylsalicylic acid doses differ from study to study. An aim of our work was to measure speed of two...

[Glomerulonephritides, histology forms, way of treatment and therapeutic effect in our patients].

B Holman, A Jezíková, M Funiaková, P Galajda, P Makovický, M Mokán

Vnitr Lek 2004, 50(6):434-437

Authors present a group of patients in the article who were monitored at a nephrology outpatient department of the University Hospital in Martin between years 1997 and 2001 for nephritic or nephrotic syndrome. Indications, contraindications and ways of histology examinations of kidneys in their department are discussed in the beginning of the work. Than prevalence of individual types of glomerulonephritides as well as way and length of therapy based on histology picture are discussed in the monitored group of patients. In the end results of therapeutic response are presented. Among other things, authors came to a conclusion that it is the least possible...

[Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].

P Lemez, J Stejskal, S Cahová, M Holub, P Svítil, J Maresová, I Vásová, L Boudová, V Benesová, D Dvoráková, J Fisar, L Slavícek

Vnitr Lek 2004, 50(6):438-446

UNLABELLED: Daunorubicin (DNR) and doxorubicin (DOX) have significant antitumor activity in acute myeloid leukemias (AML) and non-Hodgkin's lymphomas (NHL) but their use is limited by their life-threatening cumulative dose related cardiotoxicity. It is generally recommended not to administer DOX or DNR to patients in doses greater than 500 mg/sqm or 700 mg/sqm, respectively. the aim of the study was to follow up cardiotoxicity and efficacy of DNR or DOX above these limits in the 2nd complete remission (CR) patients pretreated with anthracyclines when they were given 30 minutes after cardioprotective agent dexrazoxane (DRZ) in the ratio 1:10 of DZR.RESULTS:...

[Evaluation of the antihypertensive efficacy and tolerability of fixed very low-dose perindopril/indapamid combination in patients with mild to moderate hypertension. Results of a Czech and Slovak multicentric study].

J Widimský, V Fedelesová

Vnitr Lek 2004, 50(6):447-452

AIM OF THE STUDY: To evaluate the efficacy and tolerability of fixed, low-dose perindopril (2 mg) and indapamide (0.625 mg) combination in patients with mild to moderate hypertension. Secondary aim of the study was to assess the influence of this combination on basic echocardiographic parameters.GROUP OF PATIENTS AND METHODS: 112 patients (57% men, 43 women, mean age 52 +/- 13 years) with newly diagnosed mild to moderate hypertension, without left ventricular dysfunction. 55% of patients had at least one risk factor for coronary artery disease. The following parameters were studied: BMI, sitting and upright casual blood pressure, heart rate, main...

[Infection and hemostasis].

J Hudecek, M Paceková, J Chudej, P Kubisz

Vnitr Lek 2004, 50(6):453-461

Localised and following systemic inflammatory reaction accompanying progression of infection causes generation of anti-inflammatory cytokines. They activate leucocytes, endothelium, coagulation and fibrinolysis. Sepsis is usually accompanied by already decompensated disseminated intravascular coagulation which significantly affects mortality of patients with this disease. The main cause of hypercoagulation state during sepsis seems to be inhibition of fibrinolysis as a result of overproduction of plasminogen activator inhibitor-1 in later stages of the disease. Some microorganisms have specific properties which affect individual components of hemostasis...

[Clinical importance of aspirin resistance].

J Hirmerová, J Filipovský

Vnitr Lek 2004, 50(6):462-469

The antiplatelet effect of aspirin is mostly explained by the irreversible cyclooxygenase-1 inhibition resulting in the suppression of thromboxane A2 synthesis. The benefit of aspirin was proved in various cardiovascular diseases. However, the inter- and intraindividual variability of its antiplatelet effect is well known. Aspirin resistance can be understood from the clinical point of view--as a failure of the protective effect of aspirin from thrombotic complication or can be defined from the laboratory aspect--as an inability to cause in vitro detectable platelet function inhibition. The cause of this phenomenon has not been completely explained...

[Families at risk of colon cancer I. Familial adenomatous polyposis].

T Hlavatý, L Lukác, I Duris

Vnitr Lek 2004, 50(6):470-478

Familial adenomatous polyposis (FAP) is a well-defined autosomal dominant inherited disease characterised by a diffuse polyposis of the colon and rectum leading to inevitable colorectal cancer by 50 years. The purpose of this review is to summarize the current knowledge regarding this entity with the focus on recent knowledge on genetic testing, surveillance guidelines and therapy of FAP. Available medical databases were searched from 1998 to May 2003 using keywords "familial adenomatous polyposis", followed by further search for particular issues. Additional articles were identified through the reference sections of retrieved articles and from personal...

[Comment on the "European Stroke Initiative" (EUSI) and "Recommendations for care of patients with cerebrovascular stroke", version 2002].

J Widimský, M Soucek

Vnitr Lek 2004, 50(6):479-482

[Comment by an arrhythmia specialist on the "European Stroke Initiative" (EUSI) and Recommendations on the care of patients with cerebrovascular stroke" version 2002].

R Cihák

Vnitr Lek 2004, 50(6):482-483